Thomas Nittoli

Silicon-Based Metalloprotease Inhibitors:  Synthesis and Evaluation of Silanol and Silanediol Peptide Analogues as Inhibitors of Angiotensin-Converting Enzyme¹

Mwangi wa Mutahi, Thomas Nittoli, Luxuan Guo et al. · Journal of the American Chemical Society · 2002 · 196 citations

Pharmacy, Chemistry, Pharmacology +13

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

Julian Andreev, Nithya Thambi, Andrés E. Perez Bay et al. · Molecular Cancer Therapeutics · 2017 · 164 citations

Pharmacy, Molecular Biology, Oncology +17

Silanediols: A New Class of Potent Protease Inhibitors

Scott McN. Sieburth, Thomas Nittoli, Alfred M. Mutahi et al. · Angewandte Chemie International Edition · 1998 · 136 citations

Life Sciences, Medicinal Chemistry, Pharmacology +17

Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2

Allan Wissner, Heidi L. Fraser, Charles L. Ingalls et al. · Bioorganic & Medicinal Chemistry · 2007 · 75 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as Covalent-Binding, Irreversible Inhibitors of the Kinase Domain of Vascular Endothelial Growth Factor Receptor-2

Allan Wissner, M. Brawner Floyd, Bernard D. Johnson et al. · Journal of Medicinal Chemistry · 2005 · 57 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15